FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2058903662> ?p ?o ?g. }

• W2058903662 endingPage "545" @default.
• W2058903662 startingPage "544" @default.
• W2058903662 abstract "Patients with poor-prognosis germ cell tumours according to the International Germ Cell Collaborative Group [1] face an overall survival (OS) of only approximately 50%. In three randomized trials of high-dose chemotherapy regimens compared to the standard treatment consisting of four courses of bleomycin, etoposide, and cisplatin (BEP), no superiority of dose intensification in a first-line setting could be shown [2–4]. However, in single-center studies, OS rates of up to 75% were achieved if patients were selected properly and treated in highly specialized units for medical oncology and urological surgery [5,6]. In this issue of European Urology, Huddart et al [7] present data from a randomized phase 2 trial of a doseintensified regimen (two cycles of carboplatin, bleomycin, and vincristin, two cycles of bleomycin and vincristin, and three cycles of BEP; CBOP/BEP) against the standard four courses of BEP in 89 patients. The trial was powered to achieve a favorable response rate (FRR) of 80% as defined by complete remission, partial remission with negative markers, or pathological complete remission with the new regimen. The CBOP/BEP regimen had an FRR of 74%, compared to 61% for BEP. The 2-yr OS rates were 67% and 61% for CBOP/BEP and BEP, respectively. Toxicity was high, with 96% and 63% Common Terminology Criteria grade 3 for CBOP/BEP and BEP, respectively. Five of 32 deaths were related to toxicity. The authors concluded that the 13% difference in FRR justifies an international phase 3 trial. This is critical for several reasons. (1) Patients with poor-prognosis germ cell cancer are rare, and centralized treatment in Europe has not been achieved. This is one of the main reasons why the latest EORTC trial by Daugaard et al [4] had to be stopped prematurely. Thus, it will be very difficult to accrue enough patients to prove a 13% difference in a phase 3 setting." @default.
• W2058903662 created "2016-06-24" @default.
• W2058903662 creator A5068364488 @default.
• W2058903662 date "2015-03-01" @default.
• W2058903662 modified "2023-09-26" @default.
• W2058903662 title "Poor-prognosis Germ Cell Tumours: Room for Improvement" @default.
• W2058903662 cites W1956474138 @default.
• W2058903662 cites W2027052816 @default.
• W2058903662 cites W2027976960 @default.
• W2058903662 cites W2039223396 @default.
• W2058903662 cites W2041040241 @default.
• W2058903662 cites W2124486173 @default.
• W2058903662 cites W2141256658 @default.
• W2058903662 cites W2166868261 @default.
• W2058903662 cites W2260446012 @default.
• W2058903662 cites W2569514776 @default.
• W2058903662 cites W2602637946 @default.
• W2058903662 doi "https://doi.org/10.1016/j.eururo.2014.11.009" @default.
• W2058903662 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25465972" @default.
• W2058903662 hasPublicationYear "2015" @default.
• W2058903662 type Work @default.
• W2058903662 sameAs 2058903662 @default.
• W2058903662 citedByCount "0" @default.
• W2058903662 crossrefType "journal-article" @default.
• W2058903662 hasAuthorship W2058903662A5068364488 @default.
• W2058903662 hasConcept C104317684 @default.
• W2058903662 hasConcept C143998085 @default.
• W2058903662 hasConcept C185592680 @default.
• W2058903662 hasConcept C2779122487 @default.
• W2058903662 hasConcept C55493867 @default.
• W2058903662 hasConcept C71924100 @default.
• W2058903662 hasConceptScore W2058903662C104317684 @default.
• W2058903662 hasConceptScore W2058903662C143998085 @default.
• W2058903662 hasConceptScore W2058903662C185592680 @default.
• W2058903662 hasConceptScore W2058903662C2779122487 @default.
• W2058903662 hasConceptScore W2058903662C55493867 @default.
• W2058903662 hasConceptScore W2058903662C71924100 @default.
• W2058903662 hasIssue "3" @default.
• W2058903662 hasLocation W20589036621 @default.
• W2058903662 hasLocation W20589036622 @default.
• W2058903662 hasOpenAccess W2058903662 @default.
• W2058903662 hasPrimaryLocation W20589036621 @default.
• W2058903662 hasRelatedWork W1995515455 @default.
• W2058903662 hasRelatedWork W2039318446 @default.
• W2058903662 hasRelatedWork W2080531066 @default.
• W2058903662 hasRelatedWork W2296257647 @default.
• W2058903662 hasRelatedWork W2748952813 @default.
• W2058903662 hasRelatedWork W2899084033 @default.
• W2058903662 hasRelatedWork W2980862267 @default.
• W2058903662 hasRelatedWork W3032375762 @default.
• W2058903662 hasRelatedWork W3108674512 @default.
• W2058903662 hasRelatedWork W4239340093 @default.
• W2058903662 hasVolume "67" @default.
• W2058903662 isParatext "false" @default.
• W2058903662 isRetracted "false" @default.
• W2058903662 magId "2058903662" @default.
• W2058903662 workType "article" @default.